Nearly half of people diagnosed with advanced cancer over a recent 5-year period did not undergo next-generation sequencing, according to results of a retrospective cohort study.Rates improved over ...

Foundation Medicine, Inc., a global precision medicine company, today announced an expansion to its collaboration with Bristol Myers Squibb (NYSE: BMY) to develop FoundationOne®CDx as a ...

Please provide your email address to receive an email when new articles are posted on . Real-world data show that only about 30% to 40% of patients with the most common cancers receive NGS testing.

DNA/RNA-based next-generation sequencing allows earlier diagnosis of neoplastic bile duct strictures, a prospective multicenter real-time study finds.

The US Food and Drug Administration (FDA) has released draft guidance on how sponsors can utilize next-generation sequencing (NGS) methods in nonclinical studies to assess the safety risks associated ...

Key challenges to developing "trans-tumor" targeted therapies are outlined in an editorial in the New England Journal of Medicine published Thursday by Fabrice André, head of the predictive biomarkers ...

Delays in time to first lenalidomide prescription fill for multiple myeloma. Preliminary results of a combined home and rural outpatient clinic-based infusion program through the Veterans Health ...

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported Q1 CY2026 results , with sales up 11.1% year on year ...

Located on the Buffalo Niagara Medical Campus and the first next-generation sequencing service provider in the region, UB's Genomics and Bioinformatics Core Facility provides high-quality services ...